Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc to Discuss the Topline PROPEL Results - Conference Call Transcript

Feb 11, 2021 / 09:30PM GMT
Release Date Price: $19.16 (-4.04%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Amicus Therapeutics' conference call and webcast. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Head of Investor Relations. You may begin.

Andrew Faughnan
Amicus Therapeutics, Inc. - Director of IR

Thanks, Gigi. Good afternoon. Thank you for joining our conference call to discuss top line results from the Phase III PROPEL study of AT-GAA, Amicus' novel therapy for the treatment of late onset Pompe disease. Speaking on today's call, we have John Crowley, Chairman and Chief Executive Officer; Dr. Jeff Castelli, Chief Development Officer; and Dr. Mitch Goldman, Senior Vice President and Head of Clinical Research. Also joining for Q&A from Amicus are Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; and Dr. Hung do, Chief Science Officer.

As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot